Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer
CONCLUSION: Integration of capivasertib into clinical practice is ongoing; intermittent dosing and favorable toxicity are attractive for future novel combination prospective trials.PMID:38566315 | DOI:10.1177/10600280241241531
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Alexa J Luboff David L DeRemer Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Drugs & Pharmacology | Endocrine Therapy | HER2 | Hormones | Skin | Study | Toxicology